Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code effective Oct 01, 2022
HCPCS Section
Temporary Codes for Use with Outpatient Prospective Payment System
C9098 is a valid 2026 HCPCS code meaning Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose or (Ciltacabtagene car pos t) for short. HCPCS C9098 has been effective since 10/01/2022 and applies to Medical care.
|
HCPCS Level II Code Section C - Temporary Codes for Use with Outpatient Prospective Payment System |
|
| HCPCS Code | C9098 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Pricing indicator |
53 - Statute
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Coverage code | C - Carrier judgment |
| BETOS2 code | O1D - Chemotherapy |
| HCPCS Action code | N - No maintenance for this code |
| Type of service | 1 - Medical care |
| Effective date | Effective Oct 01, 2022 |
| Date added | Added Jul 01, 2022 |
| Termination date | Sep 30, 2022 |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026
CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.